Pricing the Pathway.
An agenda for the actuarial profession. The female risk loading in life, health, and disability pricing is not biological destiny. It is a measurable downstream of a miscalibrated clinical pathway, and it is priceable at the treaty-condition level.
The current practice
Life and health actuarial tables have treated sex as a blunt demographic variable since the profession's founding. Women present at higher observed morbidity and higher total lifetime claim frequency in most lines of business. The standard response is a sex-specific rate, often expressed as a multiplicative loading against a male baseline. The loading is empirically accurate. It is also, in the framing proposed here, a partial accounting.
The observed excess is not a monolith. A material fraction of it is generated by specific, locatable, correctable failure nodes in the clinical pathway that the insured patient moves through. If a 54-year-old woman presents with atypical angina and is sent home from the emergency department with an anxiety diagnosis because the Framingham coefficients undercount her risk, the claim she files seven years later for a myocardial-infarction hospitalisation is not a product of her sex. It is a product of a risk calculator, a diagnostic threshold, and a clinical decision rule. Each of those components is named, measurable, and modifiable.
The reframe
The reframe proposed here is narrow. It does not claim female biology is identical to male biology. It claims the excess claim frequency attributable to pathway miscalibration is a pricing error and should be carried as such in treaty design, rather than absorbed as an undifferentiated demographic loading.
The observed excess female claim frequency is priced into the rate. It is interpreted as biological, absorbed as inelastic, and passed through to the insured. It cannot be reduced by any action the insurer takes.
The excess is the downstream of locatable failures (diagnostic thresholds, bundled-payment gaps, dosing errors). Each is measurable. A treaty condition can reward primary insurers for operating a corrected pathway, shifting the reinsurance book toward favorable selection.
Where the mispricing sits, concretely
Three evidence threads together establish the pathway-failure premium as a first-order actuarial concern rather than a soft-tissue observation.
Thread one: the trial-parity deficit
The IQVIA Institute 2025 review of 182 medical disorders found that female participation fell below parity (greater than 5 points below actual female disease prevalence) in 43 percent of all trials between 2015 and 2024. Three examples carry most of the actuarial weight.
The actuarial consequence of these deficits is a therapeutic efficacy curve calibrated on a male baseline that is then applied to female insureds. The female claim frequency on the back end is the predictable output.
Thread two: the pharmacokinetic signal
Zucker and Prendergast's 2020 analysis in Biology of Sex Differences reviewed 86 FDA-approved drugs. Seventy-six showed higher pharmacokinetic values in women (elevated blood concentrations, longer elimination times). Ninety-six percent of female-biased pharmacokinetics were associated with higher adverse-drug-reaction rates in women. Equal-dose prescribing, the global norm, overmedicates women by design. The observable downstream is a higher female adverse-event claim frequency that is, again, generated at the prescribing interface and not at the biological level.
Thread three: the longitudinal cardiology signal
The Wu, Haththotuwa et al. 2017 meta-analysis (22 studies, 258,000 women with preeclampsia) established a 4-fold increased heart-failure risk and 2-fold increased coronary-heart-disease, stroke, and cardiovascular-death risk post preeclampsia, adjusted for age, BMI, and diabetes. Fewer than 10 percent of women with hypertensive disorders of pregnancy receive any cardiovascular follow-up in the year postpartum (Hauspurg et al. 2019). The 4x signal therefore sits on the Medicare or commercial-insurer ledger a decade later as an untracked pathway-failure consequence of the obstetric bundle closing at delivery. See the preeclampsia essay for the full billing-architecture analysis.
What the treaty should say
The actuarial profession already has a mature contractual vocabulary for rewarding improved risk behaviour at the ceding-insurer level. Life books do this via select-and-ultimate tables and treaty-condition addenda. The pathway-failure premium is structurally compatible with that vocabulary.
A worked treaty clause set:
- Hypertensive-disorder-of-pregnancy follow-through. The ceding insurer provides evidence that female policyholders with a documented O13 or O14 code at any point in their medical history are enrolled in a cardiovascular surveillance pathway (blood pressure at 6 weeks, 6 months, and annually; lipid panel and HbA1c at year 1 and 5). The treaty returns a specified basis-point discount on the female sub-segment.
- Sex-stratified cardiovascular risk scoring. The ceding insurer demonstrates that Framingham or ASCVD outputs on female policyholders are adjusted using a validated sex-specific recalibration (e.g. QRISK3 in UK books, or a published SCORE2-recalibrated coefficient set). The treaty returns a defined basis-point discount on the female-cardiovascular sub-segment.
- Sex-stratified pharmacokinetic dosing flags. The ceding insurer's managed-care or PBM arm applies a pharmacokinetic-sex flag on a specified drug list (initial set of 10 high-ADR drugs from the Zucker review). The treaty returns a defined discount on the adverse-drug-reaction severity sub-segment.
Segment widths are illustrative of the reframe, not an empirically-pooled decomposition. The actuarial move is to replace a blanket demographic loading with a sum of addressable, measurable components. Percentages are the fraction of the standing loading each treaty clause is hypothesised to unlock.
Each clause is measurable through claim data the ceding insurer already holds. None requires new clinical infrastructure. All three are priced as reductions, not surcharges, which aligns treaty incentives with the health outcome.
Call to the profession
The Society of Actuaries and the Casualty Actuarial Society have both, in other contexts, formalised approaches to latent risk (long-tail asbestos loading, environmental reserving, climate exposures). Those precedents established that a risk category could move from "demographic, blanket, inelastic" to "attributable, measurable, manageable" through a combination of literature synthesis, data-model refinement, and contractual innovation. The present essay argues the female risk loading deserves the same treatment.
A specific next step: a joint SOA / CAS working paper proposing a taxonomy of pathway-failure drivers (diagnostic threshold miscalibration, bundled-payment gap, pharmacokinetic overdosing, trial-evidence deficit) with a mapped set of treaty-condition templates for each. The data to support it already exists. The actuarial vocabulary to express it already exists. What is absent is the convention.
This essay synthesises peer-reviewed citations carried in the ORI reproducible cost-reference dataset. Wu 2017, Zucker 2020, and IQVIA 2025 are the principal sources. The reinsurance treaty mechanics draw on the reinsurance clinical-failure essay in this suite.